Kornimate/medical-research-clean huggingface dataset:
test-retest reliability for fatigue assessment scale, short form 6 dimension and king's sarcoidosis questionnaire

Conditions: Sarcoidosis

Summary: this study aims to see if people's health related quality of life (how they feel about their health) changes over a 12 week period if they do not receive any change in their medicines. the investigators would like people to complete four questionnaires then repeat them after three months. the investigators need to do this to in order see what difference they should expect to detect if they give people treatment that works.

study design this will be a questionnaire study, which will involve administering questionnaires to patients with sarcoidosis at baseline and after six and 12 weeks. participants can either complete the questionnaires whilst they are attending clinic, or alternatively return the questionnaires via a pre-paid postal envelope. the questionnaires will be administered at the same time; no other study measures will be taken subsequently. demographic and clinical information will be collected from the patients' medical records.

Eligibility criteria:
inclusion criteria: * male or female aged over 18 * diagnosed with sarcoidosis by either; biopsy confirming non-caseating granulomas consistent with sarcoidosis, or multi-disciplinary interstitial lung disease meeting diagnosis of sarcoidosis * significant fatigue - defined as a fas score of greater than 21 points * has mental capacity to complete the questionnaires exclusion criteria: * presence of another significant cardio-respiratory disease, major organ disease (except where related to sarcoidosis) or chronic inflammatory condition
lubiprostone as a treatment for constipation in parkinson's disease

Conditions: Constipation; Parkinson's Disease

Summary: delayed colonic transient time secondary to a multi-degenerative process is the most likely cause of constipation in idiopathic pd. since lubiprostone demonstrated its ability to accelerate colonic transit time in healthy volunteers in addition to activating the chloride channels in the intestinal cells, it has the potential to improve constipation in patients with pd with no subsequent adverse events on the control of the neurological manifestation of pd. so we hypothesize the following: 1. lubiprostone will improve ratings on the bristol stool form scale (bsfs) in patients with pd induced constipation compared to baseline.(primary) 2. lubiprostone will increase the number of spontaneous bowel movements (sbm) per week, compared to baseline. (secondary) 3. lubiprostone will improve health related quality of life in subjects with pd induced constipation. ( secondary)


Eligibility criteria:
inclusion criteria: 1. age 50-85 years 2. diagnosis of parkinson's disease 3. constipation as defined by the rome iii committee 4. bsfs of more or equal to 1 and less or equal to 3 5. normal colonoscopy in the last 5 years( normal defined as absence of obstructive lesions in the colon) 6. all women subjects will be post menopausal or surgically sterile. exclusion criteria: 1. known hypersensitivity reaction to amitiza ( lubiprostone) 2. known significant adverse effects to previous treatment with lubiprostone which include; new or worsening abdominal pain, severe diarrhea, nausea, vomiting, and severe headache. 3. renal dysfunction with creatinine clearance less than 15 ml/min 4. abnormal liver enzymes or history of chronic liver disorder 5. history of bowel obstruction, , or abdominal adhesions . 6. abnormal colonoscopy ( obstructive lesions within the colon) 7. inability to give informed consent

Keywords: constipation parkinson's disease
aripiprazole in children and adolescents with bipolar i disorder

Conditions: Bipolar Disorder

Summary: the purpose of this trial is to test the safety and efficacy of two doses of aripiprazole in child and adolescent patients with bipolar i disorder, manic or mixed episode with or without psychotic features.


Eligibility criteria:
inclusion criteria: * child and adolescent patients with bipolar i disorder, manic or mixed episode with or without psychotic features exclusion criteria: * patients with certain other psychological disorders * patients with a co-morbid serious, uncontrolled systemic illness * patients with significant risk of committing suicide

Keywords: aripiprazole bipolar i disorder, manic or mixed episode with or without psychotic features
spatial proteomics profiles of aldosterone-producing adenoma and unilateral hyperplasia

Conditions: Primary Aldosteronism Due to Aldosterone Producing Adenoma; Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)

Summary: primary aldosteronism (pa) is a common cause of secondary hypertension, which is characterized by excessive aldosterone production by the adrenal gland. excessive aldosterone can significantly increase the risk of cardiovascular disease and stroke. patients with aldosterone-producing adenoma (apa) or unilateral hyperplasia (uah) can be cured by unilateral adrenalectomy. the adrenal cortex is the outer part of the adrenal gland and is subdivided into three layers- the zona glomerulosa, the zona fasciculata, and the zona reticularis. and the outermost layer is the zona glomerulosa, and it's full of cells that make the hormone aldosterone. although it has been investigated that the main cause of apa or uah is the mutations of different calcium ion channels, including kcnj5, cacna1d, clcn2 et al, it is still unknown whether there are any other changes of other proteins in different layers. therefore, the investigators designed the study to characterize the proteomics profiles of adrenal adenoma/hyperplasia leading to primary aldosterone and identify biomarkers for early identification of pa by using spatial proteomics. the samples from adrenal adenoma or hyperplasia will be collected and analyzed by spatial proteomics in hangzhou jingjie biotechnology co., ltd. the differentially expressed proteins in different layers will be screened out between apa and uah, apa and its adjacent normal tissues, and uah and its adjacent normal tissues, respectively. and kegg analysis will be conducted to determine enriched pathway in these differentially expressed protein, respectively.


Eligibility criteria:
inclusion criteria: * according to the 2020 guidelines for primary aldosteronism, patients with positive primary aldosteronism confirmed test; * patients with predominant unilateral aldosterone secretion at avs; adrenal ct suggesting unilateral adrenal adenoma (\> 0.8cm diameter) and no abnormalities in contralateral adrenal morphology. * patients who agreed to do the adrenalectomy. exclusion criteria: * adrenal ct suggests abnormal bilateral adrenal morphology or unilateral nodules. * glucocorticoids can treat aldosteronism (gra) and familial aldosteronism. * other secondary hypertension: renal parenchymal hypertension, renal artery stenosis, cushing syndrome, adrenal myeloid hyperplasia, aortic narrowing, obstructive sleep apnea hypoventilation syndrome. * any other unsuitable condition for surgery. * patients who refused to perform adrenalectomy.

Keywords: primary aldosteronism
low-dose peg-interferon plus ribavirin (ifn/rbv) for prevention of hepatocellular carcinoma (hcc) recurrence in patients who had surgery to remove primary hcc

Conditions: Hepatitis C, Chronic

Summary: the purpose of this study is to determine whether low-dose peg-interferon plus ribavirin therapy is effective in the prevention of hepatocellular carcinoma (hcc) in patients who had the curative resection of primary hcc.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of hepatocellular carcinoma due to chronic hepatitis c virus infection. * must be treated with curative treatment for primary tumor using either surgical resection or radiofrequency ablation therapy exclusion criteria: * no recurrence of hepatocellular carcinoma 3 months after the primary treatment * renal dysfunction

Keywords: hepatocellular carcinoma
concomitant administration of 13-valent pneumococcal conjugate vaccine (13vpnc) with influenza vaccine in 23-valent pneumococcal polysaccharide (23vps) pre-vaccinated adults.

Conditions: PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE

Summary: the purpose of this study is to evaluate the immunogenicity and safety of 13-valent pneumococcal polysaccharide vaccine when given concomitantly with seasonal inactivated influenza vaccine to adults 50 years and older who have previously received 23-valent pneumococcal polysaccharide vaccine.


Eligibility criteria:
inclusion criteria: 1. evidence of a personally signed and dated informed consent document (icd) indicating that the subject has been informed of all pertinent aspects of the study. 2. male or female adults 50 years of age or older. 3. documented vaccination with 1 or more prior doses of 23vps, the last given at least 1 year prior to study enrollment. 4. negative urine pregnancy test for all female subjects who are of child bearing potential. exclusion criteria: 1. previous vaccination with prevnar®, prevnar 13®, or any other investigational pneumococcal conjugate vaccine. 2. history of severe adverse reactions associated with any vaccine or vaccine-related component. 3. allergic to egg proteins (egg or egg products) and chicken proteins. 4. history of guillain-barré syndrome. 5. vaccination with any influenza vaccine within 6 months (182 days) before investigational product administration. 6. documented s pneumoniae infection within the past 5 years before investigational product administration.

Keywords: pneumococcal polysaccharide vaccine 13-valent pneumococcal conjugate vaccine invasive pneumococcal disease flu vaccine
effects of physical training on heart rate variability and exercise capacity in diabetes with autonomic neuropathy

Conditions: Diabetes Mellitus

Summary: this study aimed to investigate effects of physical training on exercise capacity and changes of heart rate variability (hrv) at rest, during exercise, and post-exercise in the patient with diabetes with autonomic neuropathy (dan).


Eligibility criteria:
inclusion criteria: * aged under 65 years old * receiving regular treatment * hba1c \< 8.0 * decreased hr response in deep breathing maneuver exclusion criteria: * heart disease * neuro-musculo-skeletal diseases * taking any medication that may affect hrv (such as α or β-blockers)

Keywords: diabetes mellitus autonomic neuropathy exercise training exercise capacity heart rate variability
testing the effects of telehealth monitoring on rehospitalization and self care for heart failure patients in home care

Conditions: Heart Failure

Summary: we are testing the use of telehealth technology that includes self monitoring of blood pressure, weight, blood sugar, and oxygen levels for patients with heart failure who are receiving home care. we are interested to learn if using the equipment results in improved self care and decreased incidence of rehospitalization.

despite telehomecare's potential to enhance patients' self-care in a cost-effective manner, few studies have evaluated its efficacy. reported studies were conducted prior to the introduction of medicare's prospective payment system for home care and evaluated the use of telehomecare in addition to traditional home visits. none examined patients' involvement in decision-making regarding the use of such technology in meeting their health care needs. available data suggest that telehomecare may improve self-care and enhance outcomes for elders with heart failure but major gaps in knowledge exist regarding the clinical and cost effectiveness of this technology when decisions regarding its use are negotiated with patients and when it substitutes for traditional nurse visits under the recently introduced changes in the financing of home health care. patient and cost outcomes will include: self-care, health care resource utilization, health status, quality of life, satisfaction, access to care and cost effectiveness. data analysis will consist of a variety of statistical tests, and estimates of treatment costs. findings will help guide optimal use of telehomecare in promoting self-care in the growing population of chronically ill elders whose conditions are characterized by high morbidity, complex therapies and poor quality and cost outcomes. subjects will be enrolled from the acute care setting and will be randomized to receive home care with or without telehealth monitoring. baseline and follow-up interviews will be conducted at admission, 60, 120 and 180 days.

Eligibility criteria:
inclusion criteria: * primary diagnosis of heart failure, english speaking; mentally competent, weigh less than 450 pounds, have a telephone in their home; have medicare insurance; are able to see, hear, place a cuff on their arm, and stand on a scale to weigh themselves, receiving home care from penn care at home. exclusion criteria: * cognitive impairment, weight \> 450 pounds, receiving disease management or on a heart transplant waiting list, receiving home care from a non- participating agency.

Keywords: heart failure
effectiveness of music therapy on blood pressure and anxiety among patients undergoing haemodialysis

Conditions: Kidney Diseases

Summary: effectiveness of music therapy on blood pressure and anxiety among patients undergoing haemodialysis

abstract introduction:- dialysis is one of the technological innovation in medicine in which patients are being reported to face psychosocial and physiological problems such as anxiety, stress and hypertension etc. to relieve these problems, music therapy has been widely used as a non-pharmacological intervention with the aim to assess the effectiveness of music therapy on blood pressure and anxiety among haemodialysis patients. methods:- current study using true experimental pre-test post-test design was conducted among 60 haemodialysis patients which were randomly allocated to experimental (30) and control (30) group using simple random sampling. the data was collected through sample characteristics performa, blood pressure monitoring data sheet and beck anxiety inventory. patients in experimental group were provided with 30 minutes of music therapy using slow and calm relaxing instrumental piano music whereas in control group only usual care was given.

Eligibility criteria:
inclusion criteria: * willing to participate in study * alert, oriented and able to comprehend, speak and listen hindi or english language. exclusion criteria: * altered sensorium * hypotension * unresponsiveness * hearing disabilities
development of an intelligent balance training system providing weight-bearing feedback in stroke patients

Conditions: Stroke

Summary: the sit-to-stand and dynamic weight-shifting ability of stroke patients is highly associated with walking performance. therefore, in order to improve the dynamic weight-shifting ability in sit-to-stand and parallel or tandem standing, a real-time visual or auditory feedback is used in our design to allow patients to realize the weight-bearing condition (by using load cells) in both sound and affected legs immediately. it can help patients to learn to control muscle to shift weight effectively which will improve patients' walking performance. by integrating physical therapy planning with electro-mechanical technology, the goal of this study is to develop a standing balance training system by requiring patients to control their center of pressure (cop) in performing sit-to-stand and maintain a standing posture via the use of their core and lower extremity musculature.

1. written informed consent must be obtained before any study specific procedures are undertaken. 1. for healthy group: participants will be recruited from the staffs and students in kaohsiung medical university (including learning university), and healthy families of cva patients in the university affiliated hospital. 2. for stroke (cva) group: we will ask the physical therapists in the university affiliated hospital to nominate the potential cva participants . the physicians will determine if they would meet the inclusion criteria before participating the present study. 2. the process of the experiment (brief describe) 1. written informed consent must be obtained before any study specific procedures are undertaken. 2. subjects who are recruited to participate in this experiment should provide the personal information forms first (ex: sex, age, height, weight, post-stroke duration, stroke type, hemiplegic side, ambulation devices etc.). then, assessment (pass, berg balance scale, timed up and go) will be conducted by a physical therapist at baseline. 3. while the stroke patients after completing the 4 -times, and 8-times training program, the above-mentioned assessment conducted again by the same physical therapist. the healthy will not receive balance training, thus .only receive one assessment.

Eligibility criteria:
inclusion criteria: 1. healthy adults a. their age should be ranged between 20 - 75 years 2. stroke patients 1. diagnosed with unilateral ischemic or hemorrhagic stroke 2. a minimum of six months post stroke 3. able to stand without support for 1 minutes 4. medically stable with physician release exclusion criteria: 1. healthy adults 1. neurological diseases 2. musculoskeletal diseases 3. rheumatic diseases 4. history of orthopedic surgery on spine or lower extremity 2. stroke patients 1. other injuries or illnesses that affect standing or walking
evaluation of clinical efficacy of pentoxifylline on patients with glomerulonephritis

Conditions: Primary Glomerulonephritis

Summary: we hypothesize that ptx might be effective in lowering proteinuria by modulating renal mcp-1 production in human glomerulonephritis.

pentoxifylline (ptx) is a phosphodiesterase inhibitor that is widely used for the treatment of peripheral vascular occlusive disorders. in addition, ptx has shown its ability to attenuate nephrotic syndrome secondary to membranous glomerulonephritis and lupus nephritis, and to reduce subnephrotic proteinuria due to early and advanced diabetic nephropathy. however, data with respect to its effect on non-nephrotic primary glomerular diseases are lacking. moreover, while the anti-proteinuric effect of ptx has been largely attributed to down-regulation of tnf-a, it remains unknown whether other mediators, especially mcp-1, are also affected by ptx. because our previous works have shown that ptx attenuates proteinuria and suppresses renal mcp-1 mrna expression in experimental glomerulonephritis in rats, we hypothesize that ptx might be effective in lowering proteinuria by modulating renal mcp-1 production in human glomerulonephritis. this study was thereby conducted to investigate the potential anti-proteinuric and anti-mcp-1 effects of ptx in subnephrotic patients with primary glomerular diseases.

Eligibility criteria:
inclusion criteria: * glomerular diseases with subnephrotic proteinuria exclusion criteria: * dm, hepatitis, systemic immunologic renal diseases

Keywords: glomerulonephritis
ca125 levels and other inflammatory markers in laparoscopic ventral hernia repair

Conditions: Hernia

Summary: the study aims to show variation in ca-125 and other inflammatory markers assumed to be a response to trauma and peritoneal inflammation in the perioperative period of laparoscopic ventral hernia repair

ca-125 and other inflammatory markers as body temperature, crp, pct, leucocytes and neutrophils measured pre- and post-operatively - correlated to trauma size i.e. area of dissection, mesh size, number of fixation points etc.

Eligibility criteria:
inclusion criteria: * adults admitted for ventral or incisional hernia repair exclusion criteria: * loss-of-domain * asa above iii * liver failure * abnormal ca-125 prior to surgery

Keywords: inflammation laparoscopy hernia incisional trauma
longitudinal evaluation of active-duty personnel with accessory pathways (lead-ap)

Conditions: Cardiac Death; Cardiac Death, Sudden; Wolf Parkinson White Syndrome

Summary: the investigators propose a secondary chart review using emr data to identify risk factors for sudden cardiac death in active-duty members diagnosed with an accessory pathway between the ages of 18-40.

the lead-ap study is a dual arm retrospective observational cohort study (using existing records) to investigate the long-term outcomes of patients diagnosed with an accessory pathway during their military service. overall objective: identifying additional risk factors associated with sudden cardiac death to help with risk stratification and guide ablation criteria for patients diagnosed with accessory pathways between the ages of 18-40. specific aim/research question: the investigators will evaluate whether patients with an ablation have improved outcomes.

Eligibility criteria:
inclusion criteria: * active duty between ages 18-40 who were diagnosed with an accessory pathway between 1/1/1990 - 5/30/2024. exclusion criteria: * patient without the diagnosis of wolf parkinson's white (wpw) syndrome

Keywords: accessory pathway ablation cardiac death wolf parkinson&#39;s white
relationship between pressure and flow velocity on coronary physiology

Conditions: Coronary Stenosis

Summary: subjects are patients who are planned to do percutaneous coronary intervention for coronary stenosis in the left circumflex artery without other stenosis in the left ascending artery and the right coronary artery, or a patient with normal coronary artery. immediately after coronary angiography or percutaneous coronary intervention, the investigators will evaluate for coronary hemodynamics by distribution of wave intensity which is calcurated by coronary pressure and flow velocity with combowire in each coronary segment. also, they will assess coronary morphology by view it in each coronary segment.

combowire (volcano therapeutics inc., ca, usa) is a 0.014 inch pressure/doppler sensor-tipped-guidewire which can measure coronary pressure and flow velocity. view it (terumo co., japan) is a guide catheter with intravascular ultrasound which can measure coronary morphology such as vessel diamter.

Eligibility criteria:
inclusion criteria: * a patient who are planned to do percutaneous coronary intervention for stenosis in the left circumflex artery without any lesions in other coronary arteries * or a patient who is performed coronary angiography without significant stenosis lesion in 3-coronary vessel exclusion criteria: * a patient with coronary stenosis with lad * hemodialysis * acute coronary syndrome * congestive heart failure * a patient with shock vitals

Keywords: coronary circulation